Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial filing for HY07121, an innovative antibody fusion protein targeting PD-1, TIGIT, and IL-15 for the treatment of advanced solid tumors. The drug candidate, classified as a Category 1 biologic, is positioned as a potential first-in-class globally.
HY07121 has shown promising results in in vivo studies, demonstrating the ability to induce the upregulation of stem cell-like T cells and NKT cell-related genes. The drug has also been shown to promote the expansion and infiltration of CD8+ T cells and NK cells within tumors. Notably, HY07121 has exhibited good efficacy in tumor models that are resistant to PD-1 inhibitors, a significant advancement in the treatment of cancers that do not respond to existing immunotherapies.
The acceptance of HY07121’s clinical trial filing by the NMPA is a critical milestone for Sichuan Huiyu as it seeks to advance this novel therapy through clinical development. The drug’s unique mechanism of action and potential to address unmet medical needs in oncology highlight the innovation within China’s biopharmaceutical industry.
As the company progresses towards clinical trials, it aims to further evaluate the safety and efficacy of HY07121 in treating advanced solid tumors. The development of this drug candidate is part of a broader trend of Chinese pharmaceutical companies focusing on research and development to bring innovative treatments to patients both domestically and internationally.- Flcube.com
